Cigna Corporation (CI) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
CI's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
CI Revenue Analysis (2013–2024)
As of February 28, 2026, Cigna Corporation (CI) generated trailing twelve-month (TTM) revenue of $268.13 billion, reflecting solid growth of +9.5% year-over-year. The most recent quarter (Q3 2025) recorded $69.75 billion in revenue, up 3.7% sequentially.
Looking at the longer-term picture, CI's 5-year compound annual growth rate (CAGR) stands at +10.0%, indicating steady revenue expansion. The company achieved its highest annual revenue of $247.12 billion in 2024, representing a new all-time high.
Revenue diversification analysis shows CI's business is primarily driven by Evernorth (81%), and Cigna Healthcare (19%). With over half of revenue concentrated in Evernorth, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including UNH (+11.8% YoY), and CVS (+7.8% YoY), CI has underperformed the peer group in terms of revenue growth. Compare CI vs UNH →
Peer Comparison
Compare CI's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CICurrent | $268.1B | +9.5% | +10.0% | 3.8% | |
| UNH | $447.6B | +11.8% | +11.7% | 4.2% | |
| CVS | $402.1B | +7.8% | +8.4% | 2.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $247.12B | +26.6% | $25.96B | 10.5% | $9.42B | 3.8% |
| 2023 | $195.26B | +8.2% | $25.18B | 12.9% | $8.54B | 4.4% |
| 2022 | $180.52B | +3.7% | $23.50B | 13.0% | $8.45B | 4.7% |
| 2021 | $174.07B | +8.5% | $22.95B | 13.2% | $7.94B | 4.6% |
| 2020 | $160.40B | +4.5% | $24.21B | 15.1% | $8.15B | 5.1% |
| 2019 | $153.57B | +215.7% | $25.08B | 16.3% | $8.08B | 5.3% |
| 2018 | $48.65B | +16.4% | $16.33B | 33.6% | $4.16B | 8.6% |
| 2017 | $41.81B | +4.9% | $14.09B | 33.7% | $3.94B | 9.4% |
| 2016 | $39.84B | +5.2% | $13.03B | 32.7% | $3.09B | 7.8% |
| 2015 | $37.88B | +8.5% | $12.45B | 32.9% | $12.36B | 32.6% |
See CI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CI Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CI vs AGIO
See how CI stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CI's revenue growth accelerating or slowing?
CI maintains +9.5% revenue growth, in line with its 5-year CAGR of +10.0%. TTM revenue stands at $268.1B. Growth rate remains consistent with historical average.
What is CI's long-term revenue growth rate?
Cigna Corporation's 5-year revenue CAGR of +10.0% reflects the sustained expansion pattern. Current YoY growth of +9.5% is near this long-term average.
How is CI's revenue distributed by segment?
CI reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.